Prognostic value of cross-lineage expression of the myeloid-associated antigens CD13 and CD33 in adult B-lymphoblastic leukemia: A large real-world study of 1005 patients - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36951610/
In real-world practice, CD13/CD33 expression can predict the risk of MRD in patients without TKI experience, but has no adverse effect on the prognosis of adult B-ALL patients. Incorporating CD13/CD33...
Conclusions: In real-world practice, CD13/CD33 expression can predict the risk of MRD in patients without TKI experience, but has no adverse effect on the prognosis of adult B-ALL patients. Incorporating CD13/CD33 into the standard antibody panels of B-ALL diagnosis and MRD measurements can help predict relapse risk and decisions on therapy options.
Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36943212/
More than 200 000 people in the US are living with a CLL diagnosis, and CLL causes approximately 4410 deaths each year in the US. Approximately two-thirds of patients eventually...
Conclusions and relevance: More than 200 000 people in the US are living with a CLL diagnosis, and CLL causes approximately 4410 deaths each year in the US. Approximately two-thirds of patients eventually need treatment. Highly effective novel targeted agents include BTK inhibitors such as acalabrutinib, zanubrutinib, ibrutinib, and pirtobrutinib or BCL2 inhibitors such as venetoclax.
Molecular associations of response to the new generation BTK inhibitor zanubrutinib in marginal zone lymphoma
Research Article | Maciej Tatarczuch, Mark Waltham, Jake Shortt, Galina Polekhina, Eliza A Hawkes, Shir-Jing Ho, Judith Trotman, Daniella Brasacchio, Melannie Co, Jessica Li, Vanitha Ramakrishnan, Karin Dunne, Stephen S....
Conclusions/Relevance: Detection of acquired BTK and PLCG2 mutations in ctDNA while on therapy is feasible and may herald clinical disease progression.
Refractory and relapsed hairy-cell leukemia (HCL): casting light on promising experimental drugs in clinical trials - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36931901/
Novel drugs will soon be available to assist standard therapy for HCL and HCLv among patients with suboptimal results following PNA treatment. In particular, the BRAF inhibitors vemurafenib and dabrafenib,...
Expert Opinion: Novel drugs will soon be available to assist standard therapy for HCL and HCLv among patients with suboptimal results following PNA treatment. In particular, the BRAF inhibitors vemurafenib and dabrafenib, with or without rituximab, have revolutionized treatment of patients with relapsed or refractory disease
Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36929591/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Relevance: CD5-positive (CD5+) DLBCL is characterized by aggressive clinical characteristics and frequent CNS relapse. In 2020, we reported the results of the primary analysis of a phase 2 study of dose-adjusted (DA)-EPOCH-R combined with high-dose (HD)-MTX (DA-EPOCH-R/HD-MTX) (PEARL5 study) with a median follow-up of 3.1 years. In this letter, we report the results of our preplanned 5-year follow-up of this study.
MALT1-dependent cleavage of CYLD promotes NF-κB signaling and growth of aggressive B-cell receptor-dependent lymphomas - Blood Cancer Journal
Source : https://www.nature.com/articles/s41408-023-00809-7
The paracaspase mucosa-associated lymphoid tissue 1 (MALT1) is a protease and scaffold protein essential in propagating B-cell receptor (BCR) signaling to NF-κB. The deubiquitinating enzyme cylindromatosis (CYLD) is a recently...
Conclusions/Relevance: Taken together, our findings identify an important role for MALT1-mediated CYLD cleavage in BCR signaling, NF-κB activation and cell proliferation, which provides novel insights into the underlying molecular mechanisms and clinical potential of inhibitors of MALT1 and ubiquitination enzymes as promising therapeutics for DLBCL, MCL and potentially other B-cell malignancies.